CN105954516A - 一种子宫内膜癌特异性检测的试剂盒 - Google Patents

一种子宫内膜癌特异性检测的试剂盒 Download PDF

Info

Publication number
CN105954516A
CN105954516A CN201610361858.XA CN201610361858A CN105954516A CN 105954516 A CN105954516 A CN 105954516A CN 201610361858 A CN201610361858 A CN 201610361858A CN 105954516 A CN105954516 A CN 105954516A
Authority
CN
China
Prior art keywords
cypa
aptamer
dna
endometrial carcinoma
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610361858.XA
Other languages
English (en)
Inventor
李静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610361858.XA priority Critical patent/CN105954516A/zh
Publication of CN105954516A publication Critical patent/CN105954516A/zh
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57442Specifically defined cancers of the uterus and endometrial
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/99Isomerases (5.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了一种特异检测子宫内膜癌的试剂盒。本发明提供的核酸适体,与人Cyclophilin A 蛋白具有较好的亲和能力。利用本发明的核酸适体,可以捕获血液中的Cyclophilin A 蛋白,通过其含量的变化来检测子宫内膜癌,将其制备成为相应的试剂盒,将用于子宫内膜癌的筛查。利用本发明的试剂盒,具有高灵敏、成本低的好处。

Description

一种子宫内膜癌特异性检测的试剂盒
技术领域
本发明涉及一种用于检测子宫内膜癌的试剂盒及其检测方法。
背景技术
子宫内膜癌作为女性生殖道三大恶性肿瘤之一,占女性生殖道恶性肿瘤的20-30%,在某些欧美国家已居女性生殖道恶性肿瘤首位,严重威胁妇女健康。随着社会发展和人类平均寿命的延长,内膜癌发病率逐年上升并伴有年轻化趋势。子宫内膜癌如果能做到早期诊断,合理治疗,其预后一般较好。子宫内膜癌的主要临床表现为不规则阴道流血,与卵巢癌等其他肿瘤不同,临床诊断主要依靠诊断性刮宫,但哺乳期或浸润型子宫内膜癌的患者,其子宫壁薄弱,刮宫时可能会造成穿孔,给患者造成伤害。
Cyclophilin A蛋白(CYPA)又称亲环素A(Gene Bank No.NP_066953),位于胞质及胞核,具有肽酰脯氨酰顺反式异构酶活性,参与蛋白质折叠、装配与运输;在细胞内与环孢素A结合,抑制T细胞活化途径,表现出免疫抑制作用,此外还参与氧化应激诱导及胆固醇代谢过程,并发挥细胞因子的功能。现有技术已经报道,通过检测人亲环素A表达水平来早期诊断子宫内膜癌。因此,检测人亲环素A变得尤为重要。
核酸适体(Aptamer,又称适配体,适配子)是能高亲和性、高特异性的结合某种生物质的单链寡核酸分子(ssDNA或ssRNA)。核酸适体是通过指数富集配体系统进化技术(Systemat1c Evolut1on of L1gands by Exponent1al enr1chment,SELEX)从人工合成的DNA/RNA文库中筛选得到的能够高度特异性结合靶标分子的单链DNA/RNA。已报道核酸适体的靶标包括金属离子、有机小分子、多肽、蛋白质、细胞甚至组织等。核酸适体的分子识别功能与抗体类似,具有与抗体分子相当甚至更强的靶标识别能力。
发明内容
本发明的目的是提供一种特异结合CYPA的核酸适体及其试剂盒。
本发明提供的核酸适体,是序列表的序列1-14所示的单链DNA。
所述核酸适体与CYPA蛋白具有较好的亲和能力。
还可将所述核酸适体进行修饰或改造,得到所述核酸适体的衍生物。
所述核酸适体的衍生物可为如下任意一种:
a)将所述核酸适体删除部分或增加部分互补的核苷酸,得到的与所述核酸适体具有相同功能的核酸适体的衍生物;
b)将所述核酸适体进行核苷酸取代或部分修饰,得到的与所述核酸适体具有相同功能的核酸适体的衍生物;
c)将所述核酸适体的骨架改造为硫代磷酸酯骨架,得到的与所述核酸适体具有相同功能的核酸适体的衍生物;
d)将核酸适体改造为肽核酸,得到的与所述核酸适体具有相同功能的核酸适体的衍生物;
e)将所述核酸适体连接上荧光、放射性和治疗性物质后,得到的与所述核酸适体具有相同功能的核酸适体的衍生物。
所述核酸适体可用于制备检测CYPA的试剂盒。
利用本发明的核酸适体,可以捕获中唾液中的中的CYPA,从而用于相关子宫内膜癌筛查。利用本发明的核酸适体,具有高灵敏、成本低、易制备、易保存的优点。本发明具有很高的应用价值。
具体实施方式
以下的实施例便于更好地理解本发明,但并不限定本发明。下述实施例中的实验方法,如无特殊说明,均为常规方法。
实施例1CYPA蛋白的获得
将Genbank:NP_066953所示的CYPA基因通过本领域常规的真核表达方式进行表达,获得了相应的目的多肽蛋白。
实施例2核酸适体的筛选和制备
设计两端包含大约20个核苷酸、中间包括个核苷酸的随机核酸文库如下:
5‘-ATCGTCACCATGGATACATG(N39)TTGCACAATTGGACAGTTAC-3’;N39代表39个随机核苷酸。
将单链DNA文库扩增为双链DNA,产物经2%琼脂糖凝胶电泳并切胶回收纯化;以回收的双链DNA为模板,体外转录出单链RNA随机文库,转录产物经PAGE纯化。75μg RNA文库经硝酸纤维素膜反筛去除与膜结合的RNA分子,然后与2ugCYPA蛋白,37℃孵育30min,反应液经硝酸纤维素膜滤过,洗涤滤膜;然后将滤膜剪碎,置于洗脱缓冲液(6mol/L尿素,0.55mol/L醋酸铵,l.5mmol/L EDTA,0.15%SDS)中煮沸5min,离心,取上清,无水乙醇沉淀RNA,并重新溶解于20μ1DEPC水中;以RNA为模板RT-PCR扩增双链DNA,体外转录出RNA文库用于下一轮筛选;每轮筛选过程中RT-PCR得到双链DNA文库,以该双链DNA为模板体外转录出RNA适配子库,筛选共进行11轮。得到了14个适配子,其序列分别为SEQ ID NO:1-14所示。具体序列如下所示:
CYPA-1:ATCGTCACCATGGATACATGACTTAACCACGCTCCATTCTATCAATTAACCCGCACTAATTGCACAATTGGACAGTTAC
CYPA-2:ATCGTCACCATGGATACATGATATATTAACCCTCACTAATCTCCTCATCCTACTATAAGTTGCACAATTGGACAGTTAC
CYPA-3:ATCGTCACCATGGATACATGCACTATATTCACGCTAAACCTTTCTTCCTCGCATACCTATTGCACAATTGGACAGTTAC
CYPA-4:ATCGTCACCATGGATACATGCTATTCCCTTTCCGCTACAATCCAATAATCACGCAACACTTGCACAATTGGACAGTTAC
CYPA-5:ATCGTCACCATGGATACATGTTATTCCTGTCTTCACACCGACTTCACATATATCTTCAATTGCACAATTGGACAGTTAC
CYPA-6:ATCGTCACCATGGATACATGCTACCGCTTCCACTCTCCTTATCCATCTTACATTCCCTC TTGCACAATTGGACAGTTAC
CYPA-7:ATCGTCACCATGGATACATGCATACTACAAACCTCCTATAATCTGTTATCAACACTAATTTGCACAATTGGACAGTTAC
CYPA-8:ATCGTCACCATGGATACATGTATTTTCTTCCACTCCCATACTTAGAATAAGAATCCACTTTGCACAATTGGACAGTTAC
CYPA-9:ATCGTCACCATGGATACATGTATGACAATTATTGCCCACTAGATACTTCCACGCAAATCTTGCACAATTGGACAGTTAC
CYPA-10:ATCGTCACCATGGATACATGACTTATCATATCCACCTTATCACATCATCCCCACTTCCT TTGCACAATTGGACAGTTAC
CYPA-11:ATCGTCACCATGGATACATGTCGTTCTCACGAATTCACACACTAACTCCCACACATACATTGCACAATTGGACAGTTAC
CYPA-12:ATCGTCACCATGGATACATGCACTATATCTTACTATCATTTAATCCTTTCACTCCCAACTTGCACAATTGGACAGTTAC
CYPA-13:ATCGTCACCATGGATACATGTCACTCCGCCGCACCACTAATTCACGCTAAACTTATCTTTTGCACAATTGGACAGTTAC
CYPA-14:ATCGTCACCATGGATACATGATTCTCTCCGAACTTCTACATATAAAACCAAGAATTCTTTTGCACAATTGGACAGTTAC
实施例3蛋白结合适配子的性能测定
将适配子分别取2.0μg,用牛小肠碱性磷酸酶(CIP)37℃消化lh,纯化回收去磷酸化的RNA;通过T4多核苷酸激酶标记[γ-32P]ATP于去磷酸化的RNA分子末端。10nmol放射性标记的适配子分别与不同浓度(1-200nM)的CYPA37℃孵育30min,各组反应液经硝酸纤维素膜滤过,洗涤滤膜,干燥滤膜,液闪计数仪测定滤膜上残留的放射量,同一样品平行做两次测定。计算各个适配子与目的蛋白的解离常数。结果如下:
名称 解离常数Kd(单位nM)
CYPA-1 11.3
CYPA-2 12.5
CYPA-3 13.0
CYPA-4 12.8
CYPA-5 12.7
CYPA-6 11.9
CYPA-7 11.4
CYPA-8 12.4
CYPA-9 12.7
CYPA-10 12.0
CYPA-11 13.1
CYPA-12 13.0
CYPA-13 12.6
CYPA-14 12.8
PBS空白对照 无结合能力
实施例4所述适配子特异性分析以及稳定性分析
分别采用人血白蛋白,免疫血清球蛋白,pg120蛋白,大肠杆菌外膜蛋白A,COCH蛋白,CYPA蛋白,与14条适配子进行特异性检测,经过结合试验发现,这些适配子都不与这些蛋白相结合,而只与CYPA蛋白结合保持较高的特异性。
将所述的适配子,取0.2ug,分别置于常温的血清、水溶液中,放置二周。通过RT-PCR检测,发现三周的放置其结构稳定,没有被降解。
实施例5所述适配子疾病的诊断
取8个子宫内膜癌患者和4个正常人的血液,使用生理盐水稀释,获得目标样本。
将14个偶联有标记的适配子分别与8个患者以及4个正常人的分泌物混合30min,通过生物素分离,定量分析其中的CYPA蛋白的含量,通过分析发现,8个子宫内膜癌患者中CYPA蛋白的含量显著增加,超过了规定的阈值。达到了子宫内膜癌的诊断标准。由此可见,其诊断效果较好。
以上仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,凡在本发明的精神和原则之内所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
序列表
〈110〉李静
〈120〉一种子宫内膜癌特异性检测的试剂盒
〈160〉14
〈210〉1
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-1
ATCGTCACCATGGATACATGACTTAACCACGCTCCATTCTATCAATTAACCCGCACTAATTGCACAATTGGACAGTTAC
〈210〉2
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-2
ATCGTCACCATGGATACATGATATATTAACCCTCACTAATCTCCTCATCCTACTATAAGTTGCACAATTGGACAGTTAC
〈210〉3
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-3
ATCGTCACCATGGATACATGCACTATATTCACGCTAAACCTTTCTTCCTCGCATACCTATTGCACAATTGGACAGTTAC
〈210〉4
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-4
ATCGTCACCATGGATACATGCTATTCCCTTTCCGCTACAATCCAATAATCACGCAACACTTGCACAATTGGACAGTTAC
〈210〉5
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-5
ATCGTCACCATGGATACATGTTATTCCTGTCTTCACACCGACTTCACATATATCTTCAATTGCACAATTGGACAGTTAC
〈210〉6
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-6
ATCGTCACCATGGATACATGCTACCGCTTCCACTCTCCTTATCCATCTTACATTCCCTCTTGCACAATTGGACAGTTAC
〈210〉7
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-7
ATCGTCACCATGGATACATGCATACTACAAACCTCCTATAATCTGTTATCAACACTAATTTGCACAATTGGACAGTTAC
〈210〉8
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-8
ATCGTCACCATGGATACATGTATTTTCTTCCACTCCCATACTTAGAATAAGAATCCACTTTGCACAATTGGACAGTTAC
〈210〉9
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-9
ATCGTCACCATGGATACATGTATGACAATTATTGCCCACTAGATACTTCCACGCAAATCTTGCACAATTGGACAGTTAC
〈210〉10
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-10
ATCGTCACCATGGATACATGACTTATCATATCCACCTTATCACATCATCCCCACTTCCTTTGCACAATTGGACAGTTAC
〈210〉11
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-11
ATCGTCACCATGGATACATGTCGTTCTCACGAATTCACACACTAACTCCCACACATACATTGCACAATTGGACAGTTAC
〈210〉12
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-12
ATCGTCACCATGGATACATGCACTATATCTTACTATCATTTAATCCTTTCACTCCCAACTTGCACAATTGGACAGTTAC
〈210〉13
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-13
ATCGTCACCATGGATACATGTCACTCCGCCGCACCACTAATTCACGCTAAACTTATCTTTTGCACAATTGGACAGTTAC
〈210〉14
〈211〉 79
〈212〉DNA
〈213〉人工序列
〈400〉CYPA-14
ATCGTCACCATGGATACATGATTCTCTCCGAACTTCTACATATAAAACCAAGAATTCTTTTGCACAATTGGACAGTTAC

Claims (3)

1.一种用于子宫内膜癌检测的试剂盒,其含有能特异性与CYPA蛋白特异性结合的核酸适体。
2.如权利要求1所述的试剂盒,其特征在于:所述核酸适体的序列如SEQ ID No:13所述。
3. 一种检测子宫内膜癌的方法,其特征在于利用权利要求1所述的试剂盒。
CN201610361858.XA 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒 Pending CN105954516A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610361858.XA CN105954516A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610361858.XA CN105954516A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201510807002.6A CN105223358B (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201510807002.6A Division CN105223358B (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒

Publications (1)

Publication Number Publication Date
CN105954516A true CN105954516A (zh) 2016-09-21

Family

ID=54992426

Family Applications (10)

Application Number Title Priority Date Filing Date
CN201610361860.7A Pending CN105866411A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610370068.8A Pending CN105842446A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610361916.9A Pending CN105807069A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610361857.5A Pending CN105807068A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201510807002.6A Active CN105223358B (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610370066.9A Pending CN105842445A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610369946.4A Pending CN105866412A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610361859.4A Pending CN105807054A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610361858.XA Pending CN105954516A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610361917.3A Pending CN105842444A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒

Family Applications Before (8)

Application Number Title Priority Date Filing Date
CN201610361860.7A Pending CN105866411A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610370068.8A Pending CN105842446A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610361916.9A Pending CN105807069A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610361857.5A Pending CN105807068A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201510807002.6A Active CN105223358B (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610370066.9A Pending CN105842445A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610369946.4A Pending CN105866412A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒
CN201610361859.4A Pending CN105807054A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610361917.3A Pending CN105842444A (zh) 2015-11-22 2015-11-22 一种子宫内膜癌特异性检测的试剂盒

Country Status (1)

Country Link
CN (10) CN105866411A (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105886659A (zh) * 2016-06-29 2016-08-24 北京泱深生物信息技术有限公司 Dstn基因及其表达产物作为子宫内膜癌的诊治靶标

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078645A1 (en) * 2001-10-23 2003-04-24 Pigott John D. Steerable catheter and method for locating coronary sinus
CN104830867A (zh) * 2015-06-07 2015-08-12 杨洋 一种能够特异性结合癌细胞中的dkk1蛋白的适配子

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451609B1 (en) * 1996-05-30 2002-09-17 The Cleveland Clinic Foundation Method of detecting gynecological carcinomas
CN101261279B (zh) * 2008-04-11 2012-07-04 四川大学 子宫内膜癌诊断试剂、试剂盒及防治药物
GB201001444D0 (en) * 2010-01-29 2010-03-17 Cambridge Entpr Ltd Biomarkers
AU2014209218B2 (en) * 2013-01-25 2018-06-07 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
CN104109667B (zh) * 2014-06-24 2017-04-05 叶尚勉 一种核酸片段及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078645A1 (en) * 2001-10-23 2003-04-24 Pigott John D. Steerable catheter and method for locating coronary sinus
CN104830867A (zh) * 2015-06-07 2015-08-12 杨洋 一种能够特异性结合癌细胞中的dkk1蛋白的适配子

Also Published As

Publication number Publication date
CN105807054A (zh) 2016-07-27
CN105223358A (zh) 2016-01-06
CN105842445A (zh) 2016-08-10
CN105842444A (zh) 2016-08-10
CN105807068A (zh) 2016-07-27
CN105866412A (zh) 2016-08-17
CN105223358B (zh) 2016-09-14
CN105807069A (zh) 2016-07-27
CN105842446A (zh) 2016-08-10
CN105866411A (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
CN105203763B (zh) 一种口腔癌特异性检测的试剂盒
CN105223358B (zh) 一种子宫内膜癌特异性检测的试剂盒
CN105785007A (zh) 一种子宫内膜癌特异性检测的试剂盒
CN105823895A (zh) 一种子宫内膜癌特异性检测的试剂盒
CN105823879A (zh) 一种子宫内膜癌特异性检测的试剂盒
CN105823894A (zh) 一种子宫内膜癌特异性检测的试剂盒
CN105353126B (zh) 一种唇癌特异性检测的试剂盒
CN106018839A (zh) 一种用于检测眼科疾病的试剂盒及其检测方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160921

WD01 Invention patent application deemed withdrawn after publication